



an Open Access Journal by MDPI

The Future Direction of Radiopharmaceutical Development for Cancer Theranostics

Guest Editor:

Dr. Martina Benešová-Schäfer

Research Group Molecular
Biology of Systemic
Radiotherapy, Research Program
Imaging and Radiooncology,
German Cancer Research Center
(DKFZ), Im Neuenheimer Feld
223, 69120 Heidelberg, Germany

Deadline for manuscript
submissions:
closed (31 January 2020)

Message from the Guest Editor

Dear Colleagues

The journal *Pharmaceuticals* is planning to publish a Special Issue covering the topic “The Future Direction of Radiopharmaceutical Development for Cancer Theranostics”, and I am cordially inviting you to contribute an article to this volume.

The purpose of this Special Issue is to host research and review papers on the development of novel radiopharmaceuticals and therapy strategies for cancer theranostics, which hold a great promise for improved patients' outcomes in the future. Areas of interest include, but are not limited to:

- Identification of new targets for cancer theranostics;
- Design of novel radiopharmaceuticals for cancer theranostics;
- Evaluation of non-standard radionuclides potentially suitable for cancer theranostics;
- Experimental targeted radionuclide therapy strategies;
- Prospective combination therapy with targeted radionuclide therapy involved.



mdpi.com/si/28102

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com